BR9609503A - Composto, uso de um composto, processo de tratamento de condições onde a inibição de pde especìfico para cgmp é de benefìcio terapêutico, em corpo de animal humano ou não humano, composição farmacêutica, e processos para preparar a mesma e um composto - Google Patents

Composto, uso de um composto, processo de tratamento de condições onde a inibição de pde especìfico para cgmp é de benefìcio terapêutico, em corpo de animal humano ou não humano, composição farmacêutica, e processos para preparar a mesma e um composto

Info

Publication number
BR9609503A
BR9609503A BR9609503-2A BR9609503A BR9609503A BR 9609503 A BR9609503 A BR 9609503A BR 9609503 A BR9609503 A BR 9609503A BR 9609503 A BR9609503 A BR 9609503A
Authority
BR
Brazil
Prior art keywords
compound
human
pgmp
inhibition
prepare
Prior art date
Application number
BR9609503-2A
Other languages
English (en)
Inventor
Alain Claude-Marie Daugan
Richard Frederic Labaudiniere
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Publication of BR9609503A publication Critical patent/BR9609503A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"COMPOSTO, USO DE UM COMPOSTO, PROCESSO DE TRATAMENTO DE CONDIçõES ONDE A INIBIçãO DE PDE ESPECìFICO PARA CGMP é DE BENEFìCIO TERAPêUTICO, EM UM CORPO DE ANIMAL HUMANO OU NãO HUMANO, COMPOSIçãO FARMACêUTICA, E, PROCESSOS PARA PREPARAR A MESMA E UM COMPOSTO". Um composto de fórmula (I): e sais e solvatos dos mesmos, em que: R° representa hidrogênio, halogênio ou alquila C~ 1-6~; R^ 1^ é selecionado dentre o grupo consistindo de: (a) hidrogênio; (b) alquila C~ 1-6~ opcionalmente substituída por um ou mais substituintes selecionados dentre fenila, halogênio, -CO~ 2~R^ a^ e -NR^ a^R^ b^; (c) cicloalquila C~ 3-6~; (d) fenila; e (e) um anel heterocíclico de 5- ou 6- membros contendo pelo menos um heteroátomo selecionado dentre oxigênio, nitrogênio e enxofre, e sendo opcionalmente substituído por uma ou mais alquila C~ 1-6~, e opcionalmente ligado ao átomo de nitrogênio que R^ 1^ é fixado via alquila C~ 1-6~; R^ 2^ é selecionado dentre o grupo consistindo de: (f) cicloalquila C~ 3-6~; (g) fenila opcionalmente substituída por um ou mais substituintes selecionados dentre -OR^ a^, -NR^ a^R^ b^, halogênio, hidroxi, trifluorometila, ciano e nitro; (h) um anel heterocíclico com 5- ou 6- membros contendo pelo menos um heteroátomo selecionado dentre oxigênio, nitrogênio e enxofre; e (i) um anel bicíclico (1) fixado no resto de uma via de molécula de átomos de carbono do anel benzeno e A é um anel heterocíclico com 5- ou 6- membros como definidos no ponto (h); e R^ a^ e R^ b^ independentemente representam hidrogênio ou alquila C~ 1-6~. Um composto da presente invenção é um inibidor potente e seletivo de PDE específico para cGMP tendo utilidade em várias áreas terapêuticas onde esta inibição é benéfica.
BR9609503-2A 1995-07-14 1996-07-11 Composto, uso de um composto, processo de tratamento de condições onde a inibição de pde especìfico para cgmp é de benefìcio terapêutico, em corpo de animal humano ou não humano, composição farmacêutica, e processos para preparar a mesma e um composto BR9609503A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9514473.9A GB9514473D0 (en) 1995-07-14 1995-07-14 Chemical compounds
PCT/EP1996/003023 WO1996032003A2 (en) 1995-07-14 1996-07-11 Tetrahydroimidazopyridoindolediones and their use as medicaments

Publications (1)

Publication Number Publication Date
BR9609503A true BR9609503A (pt) 2000-03-08

Family

ID=10777704

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9609503-2A BR9609503A (pt) 1995-07-14 1996-07-11 Composto, uso de um composto, processo de tratamento de condições onde a inibição de pde especìfico para cgmp é de benefìcio terapêutico, em corpo de animal humano ou não humano, composição farmacêutica, e processos para preparar a mesma e um composto

Country Status (13)

Country Link
US (3) US6001847A (pt)
EP (1) EP0859778B1 (pt)
JP (1) JP4012246B2 (pt)
CN (1) CN1095841C (pt)
AT (1) ATE211139T1 (pt)
AU (1) AU702548B2 (pt)
BR (1) BR9609503A (pt)
CA (1) CA2226759A1 (pt)
DE (1) DE69618231T2 (pt)
ES (1) ES2170252T3 (pt)
GB (1) GB9514473D0 (pt)
MX (1) MX9800415A (pt)
WO (1) WO1996032003A2 (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2294480C (en) 1997-06-23 2008-05-20 Queen's University At Kingston Microdose therapy of female sexual dysfunction by no, co, and their donors
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
CA2339630C (en) * 1998-09-16 2006-05-23 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors
US6451807B1 (en) * 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
NO20002097L (no) 1999-04-30 2001-10-26 Lilly Icos Llc Fremstillingsgjenstander
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
CA2407031A1 (en) 2000-04-19 2001-10-25 Lilly Icos Llc Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
CA2412596C (en) 2000-06-23 2007-07-31 Lilly Icos Llc Cyclic gmp-specific phosphodiesterase inhibitors
MXPA03002909A (es) 2000-10-02 2003-09-10 Lilly Icos Llc Compuestos quimicos.
DE60121461T2 (de) 2000-10-03 2007-02-08 Lilly Icos Llc, Wilmington Kondensierte pyridoindolderivate
EP1366760B1 (en) * 2001-02-15 2010-06-30 Mitsubishi Tanabe Pharma Corporation Tablets quickly disintegrated in oral cavity
DE10118306A1 (de) 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
ES2278956T3 (es) * 2001-04-25 2007-08-16 Lilly Icos Llc Derivados de carbolina como inhibidores de fosfodiesterasa 5 (pde5) para el tratamiento de enfermedades cardiovasculares y de la disfuncion erectil.
EP1401835A1 (en) 2001-06-05 2004-03-31 Lilly Icos LLC Carboline derivatives as pde-5 inhibitors
ES2337887T3 (es) * 2001-12-20 2010-04-30 Merck Serono Sa Derivados de pirrolidina en calidad de moduladores de prostaglandina.
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7208516B2 (en) * 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
ES2211295B1 (es) * 2002-07-19 2005-12-01 Consejo Sup. De Investig. Cientificas Tetrahidro-beta-carbolinas fenolicas como antioxidantes.
ES2318175T3 (es) * 2002-07-31 2009-05-01 Lilly Icos Llc Reaccion pictet-splenger modificada y productos preparados a partir de la misma.
US20050048573A1 (en) * 2003-02-03 2005-03-03 Plexxikon, Inc. PDE5A crystal structure and uses
DK1606261T3 (da) 2003-03-10 2010-01-18 Nycomed Gmbh Hidtil ukendt fremgangsmåde til fremstilling af roflumilast
US20070010450A1 (en) 2003-06-13 2007-01-11 Microbia, Inc., A Massachusetts Corporation Methods and compositions for the treatment of gastrointestinal disorders
DE10348022A1 (de) * 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
MXPA06010542A (es) * 2004-03-15 2007-03-28 Ptc Therapeutics Inc Derivados de carbolina tetra-ciclica para la inhibicion de angiogenesis.
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
EA201200555A1 (ru) 2004-03-15 2013-01-30 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Производные карболина, полезные в ингибировании ангиогенеза
JP2008509971A (ja) 2004-08-18 2008-04-03 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｅｇ５キネシンのインヒビターとして使用するためのベンゾチエノピリジン
AU2006224619B2 (en) * 2005-03-16 2012-06-07 Takeda Gmbh Taste masked dosage form containing roflumilast
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
NZ571357A (en) 2006-02-22 2010-11-26 4Sc Ag Indolopyridines as EG5 kinesin modulators
WO2007113243A2 (en) * 2006-03-31 2007-10-11 Investigación Y Clínica Andrológicas S.L. Use of pde 5 inhibitors for the treatment of overactive bladder
FR2912405A1 (fr) * 2007-02-08 2008-08-15 Fourtillan Snc Derives des imidazo[1',5':1,6]pyrido[3,4-b]indoles et leur utilisation en therapeutique
BRPI0721950A2 (pt) * 2007-08-22 2015-09-29 4Sc Ag indolopiridinas como inibidores da proteína de fuso de cinesina
EP2098524A1 (en) * 2008-03-05 2009-09-09 4Sc Ag Process for preparing enantiomerically pure indolopyrinidines
MX2010010334A (es) * 2008-03-24 2010-10-08 Celgene Corp Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida.
KR102367876B1 (ko) 2013-11-22 2022-02-24 사브레 테라퓨틱스 엘엘씨 오토탁신 억제제 화합물
CA2930735A1 (en) * 2013-11-22 2015-05-28 Sabre Therapeutics Llc Tetracyclic autotaxin inhibitors
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
JP6687550B2 (ja) 2014-06-23 2020-04-22 セルジーン コーポレイション 肝疾患又は肝機能異常を治療するためのアプレミラスト
EA036337B1 (ru) 2015-05-27 2020-10-28 Сабре Терапьютикс Ллс Ингибиторы аутотаксина и их применения
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644384A (en) * 1969-06-09 1972-02-22 Sterling Drug Inc Certain 2-(alpha-haloacetyl) - 1 2 3 4-tetrahydro - 9h - pyrido(3 4-b)indole-3-carboxylates and derivatives
US3717638A (en) * 1971-03-11 1973-02-20 Sterling Drug Inc 1,2,3,4,6,7,12,12A-OCTAHYDRO-2-PHENYLPYRAZINO[2',1':6,1]PYRIDO[3,4-b]INDOLES AND INTERMEDIATES THEREFOR
US3917599A (en) * 1973-03-30 1975-11-04 Council Scient Ind Res 2-Substituted-1,2,3,4,6,7,12,12A-octahydropyrazino(2{40 ,1{40 :6,1)pyrido(3,4-B)indoles
GB1454171A (en) * 1973-10-19 1976-10-27 Council Scient Ind Res Tetracyclic compounds
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
GR79603B (pt) * 1982-07-24 1984-10-31 Pfizer
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
IT1217190B (it) * 1988-04-22 1990-03-14 Recordati Chem Pharm Composti utili per il trattamento e diagnosi di disfunzioni frettili
EP0357122A3 (en) * 1988-08-29 1991-10-23 Duphar International Research B.V Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties
DE3830096A1 (de) * 1988-09-03 1990-03-15 Hoechst Ag Piperazindione mit psychotroper wirkung
FR2649613B1 (fr) * 1989-07-11 1991-09-27 Virag Ronald Medicament vaso-actif
JPH0344324A (ja) * 1989-07-13 1991-02-26 Kazuoki Tsuchiya 性機能賦活剤
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
DK0459666T3 (da) * 1990-05-31 1994-12-05 Pfizer Lægemidler mod impotens
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
CA2188385C (en) * 1994-04-22 2000-07-11 Ragab El-Rashidy Dosage forms and method for ameliorating male erectile dysfunction
US5874437A (en) * 1996-11-01 1999-02-23 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses

Also Published As

Publication number Publication date
DE69618231T2 (de) 2002-08-22
EP0859778B1 (en) 2001-12-19
EP0859778A2 (en) 1998-08-26
US6001847A (en) 1999-12-14
WO1996032003A3 (en) 1997-01-03
WO1996032003A2 (en) 1996-10-17
US6143757A (en) 2000-11-07
DE69618231D1 (de) 2002-01-31
ES2170252T3 (es) 2002-08-01
GB9514473D0 (en) 1995-09-13
CN1195350A (zh) 1998-10-07
CA2226759A1 (en) 1996-10-17
US6218400B1 (en) 2001-04-17
JP4012246B2 (ja) 2007-11-21
ATE211139T1 (de) 2002-01-15
JPH11509517A (ja) 1999-08-24
MX9800415A (es) 1998-04-30
AU6613896A (en) 1996-10-30
CN1095841C (zh) 2002-12-11
AU702548B2 (en) 1999-02-25

Similar Documents

Publication Publication Date Title
BR9916282A (pt) Composto, uso de um um composto e método de tratamento
PA8452201A1 (es) Derivados de 9-desoxo-9a-aza-9a -homoeritromicina a c-4"sustituidos.
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BR0116323A (pt) Compostos de heterociclilindazol e -azaindazol como ligandos de 5-hidroxitriptamina-6
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
BR0111358A (pt) Compostos de tioacetamida e seu uso
BR9910849A (pt) Composto, processo para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, tal como um humano, formulação farmacêutica, uso de um composto, processo para preparação do composto, e, derivado protegido.
BR9714082A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto.
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
BRPI0113042B8 (pt) composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato
ES2133324T3 (es) Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso.
ES2063073T3 (es) Derivados de arilmetilenilo conocidos y nuevos seleccionados de tiazolidinonas, imidazolidinonas y oxazolidinonas utiles como agentes antialergicos y agentes antiinflamatorios.
BR9805544C1 (pt) Uso de um composto.
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
DK599789A (da) 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,3,4-thiadazoler og -oxadiazoler samt 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,2,4-thiadazoler, -oxadiazoler og -triazoler som anti-inflammatoriske midler
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
UA41355C2 (uk) Засіб для лікування нейро-сніду
BR0116481A (pt) Compostos de heterociclilalquilindol ou azaindol como ligandos de 5-hidroxitriptamina-6
BR0315777A (pt) Uso de derivados de piperazina como antagonistas ccr1
BR0009524A (pt) Uso de um composto, e, composição farmacêutica ou veterinaria
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
BR0307588A (pt) Composto, inibidor de gsk-3, composição farmacêutica, e, agente terapêutico ou preventivo para uma doença
BR9304780A (pt) Composto, processo para preparar o composto, composição farmacêutica e uso
PT986393E (pt) Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro
NZ511559A (en) Use of staurosporine derivatives for treating ocular neovascular diseases

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B24C Patent annual fee: request for for restoration

Free format text: REFERENTE A 13A,14A E 15A ANUIDADE(S).

B24H Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)
B24F Patent annual fee: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2259 DE 22/04/2014 POR TER SIDO INDEVIDA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AS 13A, 14A E 15A ANUIDADES.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2606 DE 15-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.